- Home
- RGC vs EXEL Comparison
RGC vs EXEL Comparison
Compare RGC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGC | EXEL |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 11.4B |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RGC | EXEL |
|---|---|---|
| Price | $29.65 | $46.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $46.50 |
| AVG Volume (30 Days) | 156.2K | ★ 2.0M |
| Earning Date | 10-31-2025 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | N/A | $13.61 |
| Revenue Next Year | N/A | $13.13 |
| P/E Ratio | ★ N/A | $16.52 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.39 | $33.76 |
| 52 Week High | $950.00 | $48.74 |
Technical Indicators
Market Signals| Indicator | RGC | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 54.37 | 64.15 |
| Support Level | $22.43 | $40.53 |
| Resistance Level | $34.60 | N/A |
| Average True Range (ATR) | 2.65 | 1.23 |
| MACD | -0.07 | 0.20 |
| Stochastic Oscillator | 26.34 | 87.83 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.